Back to Hematology
Hematologyv2019Evidence-Based

BALL Score for Relapsed/Refractory CLL

Assesses prognosis of patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL) on targeted therapies. The BALL Score (β2-microglobulin, Anemia, LDH, Last Therapy) helps estimate survival outcomes in patients with R/R-CLL who require further treatment with targeted therapies.

Clinical Input Parameters

mg/dL
Range: 0.1 — 50 mg/dL
g/dL
Range: 3 — 20 g/dL
U/L
Range: 50 — 5000 U/L
U/L
Range: 100 — 500 U/L
months
Range: 0 — 600 months
Clinical Assessment
Awaiting Parameters
ball score
—points
Ready to Calculate

Awaiting Clinical Input

Enter the clinical input parameters on the left and click Run Clinical Assessment to evaluate this medical calculator with deterministic clinical scoring.

Open in Web App
Clinical decision support tool for licensed medical practitioners. Confirm independently before prescribing or clinical action.

When & Why to Use

The BALL Score for Relapsed/Refractory CLL is utilized in clinical practice for risk stratification, diagnostic probability estimation, and treatment decision-making within hematology.

Use this tool during initial patient intake, emergency department workup, or bedside assessment when objective clinical scoring is required to guide management or admission decisions.

Clinical Formula & Scoring Logic

BALL Score = β2-microglobulin points + Anemia points + LDH points + Last therapy points

Clinical Pearls & Practice Notes

  • BALL stands for: Beta-2-microglobulin, Anemia, LDH, Last therapy
  • Score was derived from studies using ibrutinib, idelalisib, and venetoclax
  • Does not encompass all potential prognostic variables for R/R-CLL
  • Results should be interpreted within broader clinical context
  • Anemia defined as Hgb <12 g/dL for men, <11 g/dL for women

Evidence & Literature Citations

  1. Soumerai JD, Ni A, Xing G, Huang J, Furman RR, Jones J, et al. Evaluation of the CLL-IPI in relapsed and refractory chronic lymphocytic leukemia in idelalisib phase-3 trials. Leuk Lymphoma. 2019 Jun;60(6):1438-1446. doi: 10.1080/10428194.2018.1540782.
  2. Soumerai JD, Ni A, Darif M, Londhe A, Xing G, Mun Y, et al. Prognostic risk score for patients with relapsed or refractory chronic lymphocytic leukaemia treated with targeted therapies or chemoimmunotherapy: a retrospective, pooled cohort study with external validations. Lancet Haematol. 2019 Jul;6(7):e366-e374. doi: 10.1016/S2352-3026(19)30085-7.
  3. Gentile M, Morabito F, Del Poeta G, Mauro FR, Reda G, Sportoletti P, et al. Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study. Leukemia. 2021 Jan;35(1):235-238. doi: 10.1038/s41375-020-0816-y.

Score Interpretation Ranges

Low Risk0 – 1 pts

Low risk group

Intermediate Risk2 – 3 pts

Intermediate risk group

High Risk4 – 4 pts

High risk group

Need Clinical Suite Access?

Run this calculator with patient history, laboratory integration, and drug interaction safety checks on the DexaMed clinician app.

Open in Web App

Clinical Decision Support (CDS) Notice & Legal Disclaimer

This medical calculator and its scoring interpretation are provided strictly for licensed healthcare professionals and medical trainees as an educational and clinical decision support instrument. It does not replace independent clinical judgment, comprehensive patient history, physical examination, or attending physician oversight. Not FDA-cleared as an autonomous diagnostic medical device. Read the full DexaMed Medical Disclaimer.